MAPT and Alzheimer disease: Taken together, our findings in humans support a role of DAM2 in mitigating neocortical accumulation of insoluble tau aggregates, which place microglial activation in the center of the amyloid cascade hypothesis for AD29,30, suggesting that it should be taken into account in future AD therapies14,15.